Cite
HARVARD Citation
Spicer, J. et al. (n.d.). 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis. Journal for immunotherapy of cancer. p. A387. [Online].